Work

Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx513.007

Authors: A. Jayaram, K. Nowakowska, J. Mateo, T. Hernandez, S. Kumar, B. Fulton, D. Nava Rodrigues, R. Riisnaes, A. Zukiwski, S. Proniuk, A.S. Bexon, J. Bisaha, D. Bianchini, Z. Zafeiriou, R.P. Lopez, N. Tunariu, S. Pacey, R. Jones, J. Sebastian de Bono, G. Attard

Institution: Institute of Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2763470497

FWCI: 0.454

Cites:

Cited by: 3

Related to: 10